Impact of the Duration of Trimethoprim–Sulfamethoxazole Prophylaxis on the Incidence of Infection After Kidney Transplantation: A Target Trial Emulation Study Within the Swiss Transplant Cohort Study (STCS)—The QUID‐PRO‐QUO Study (QUIDney Transplantation and Duration of PROphylaxis With QUO‐Trimoxazole)
Transplant Infectious Disease · 2025-09 · 27 (5)
DOI: 10.1111/tid.70106 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant Infectious Disease, online erschienen am 18.09.2025. Verfasst von Aline Munting und 18 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Service,University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Kidney Transplantation, Trimethoprim, Sulfamethoxazole Drug Combination, Antibiotic Prophylaxis, Bacterial Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moritz Strauss Foundation, Swiss University Hospitals, Swiss National Science Foundation.
Abstract (Originalsprache)
Background
Trimethoprim–sulfamethoxazole prophylaxis effectively prevents opportunistic and non‐opportunistic infections in kidney transplantation, but optimal duration remains uncertain. This study investigated whether extending TMP–SMX prophylaxis is associated with lower infection rates.
Methods
This target trial emulation using observational data from the Swiss Transplant Cohort Study compared short (< 7 months) versus long (≥ 7 months) TMP–SMX prophylaxis. The primary outcome was bacterial infection potentially susceptible to TMP–SMX up to 12‐months post‐transplant. Inverse probability weighting (IPW) adjusted for confounders including age, living donation, lymphocyte counts, use of antithymocyte globulin, acute rejection, CMV infection, and transplant center. All bacterial and opportunistic infections, kidney function, and patient and allograft survival were summarized descriptively.
Results
A total of 1700 KTRs fulfilled inclusion criteria; 1325 (78%) participants received a short prophylaxis and 375 (22%) received a long prophylaxis. Median TMP–SMX duration was 179 days in the short group and 280 days in the long group. At 12‐month post‐transplant, the primary outcome was observed in 120/1325 (9.1%) in the short group and 43/375 (11.5%) in the long group. IPW analysis estimated an adjusted risk difference of 2.11% (95% CI −0.47% to 5.27%). Center, rejection, and use of ATG were associated with longer TMP–SMX duration, but risk difference was similar before and after weighting. Urinary tract infection was the most common bacterial infection. Opportunistic and overall infection rates, kidney function, and patient and graft survival were similar among groups.
Conclusions
In this target trial emulation, no differences in bacterial infection rates at 12‐month post‐transplant was observed between short and long TMP–SMX prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Service,University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
- Department of Clinical Research, Division of Clinical Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Clinic of Nephrology and Transplantation Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Division of Infectious Diseases, Infection Prevention and Travel Medicine, HOCH Health Ostschweiz Kantonsspital St. Gallen, University Teaching and Research Hospital, St. Gallen, Switzerland.
- Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
- Clinical Trial Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Förderung
- Moritz Strauss Foundation
- Swiss University Hospitals
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Munting, A., Chammartin, F., Binet, I., Boggian, K., Dickenmann, M., Froissart, M., Garzoni, C., Golshayan, D., Haidar, F., Hirzel, C., Hübel, K., Huynh-Do, U., Khanna, N., Koller, M., Mueller, N., Sidler, D., van Delden, C., Manuel, O., & Swiss Transplant Cohort Study (2025). Impact of the Duration of Trimethoprim–Sulfamethoxazole Prophylaxis on the Incidence of Infection After Kidney Transplantation: A Target Trial Emulation Study Within the Swiss Transplant Cohort Study (STCS)—The QUID‐PRO‐QUO Study (QUIDney Transplantation and Duration of PROphylaxis With QUO‐Trimoxazole). Transplant Infectious Disease, 27(5). https://doi.org/10.1111/tid.70106
Vancouver
Munting A, Chammartin F, Binet I, Boggian K, Dickenmann M, Froissart M, et al. Impact of the Duration of Trimethoprim–Sulfamethoxazole Prophylaxis on the Incidence of Infection After Kidney Transplantation: A Target Trial Emulation Study Within the Swiss Transplant Cohort Study (STCS)—The QUID‐PRO‐QUO Study (QUIDney Transplantation and Duration of PROphylaxis With QUO‐Trimoxazole). Transplant Infectious Disease. 2025;27(5). doi:10.1111/tid.70106
BibTeX
@article{Munting2025,
author = {Munting, Aline and Chammartin, Frédérique and Binet, Isabelle and Boggian, Katia and Dickenmann, Michael and Froissart, Marc and Garzoni, Christian and Golshayan, Dela and Haidar, Fadi and Hirzel, Cédric and Hübel, Kerstin and Huynh-Do, Uyen and Khanna, Nina and Koller, Michael and Mueller, Nicolas and Sidler, Daniel and van Delden, Christian and Manuel, Oriol and Swiss Transplant Cohort Study, Swiss Transplant Cohort Study},
title = {Impact of the Duration of Trimethoprim–Sulfamethoxazole Prophylaxis on the Incidence of Infection After Kidney Transplantation: A Target Trial Emulation Study Within the Swiss Transplant Cohort Study (STCS)—The QUID‐PRO‐QUO Study (QUIDney Transplantation and Duration of PROphylaxis With QUO‐Trimoxazole)},
journal = {Transplant Infectious Disease},
year = {2025},
volume = {27},
number = {5},
doi = {10.1111/tid.70106}
}
EUVIMED